Silence Therapeutics said the US Patent and Trade Mark Office yesterday granted it with two new patents.
US patent application 15/589,968 was granted as US Patent 9,790,501 and US patent application 15/594,438 as US Patent 9,790,505.
"These grants provide further protection for our US patent estate," chief executive Ali Mortazavi said.
"We now have ten granted US patents, one US patent application, three granted European patents and four European patent applications encompassing our chemical modification technology."
At 9:03am: (LON:SLN) Silence Therapeutics PLC share price was -0.5p at 234.5p